ATE519755T1 - Modulatoren des vitamin-d-rezeptors - Google Patents

Modulatoren des vitamin-d-rezeptors

Info

Publication number
ATE519755T1
ATE519755T1 AT05854993T AT05854993T ATE519755T1 AT E519755 T1 ATE519755 T1 AT E519755T1 AT 05854993 T AT05854993 T AT 05854993T AT 05854993 T AT05854993 T AT 05854993T AT E519755 T1 ATE519755 T1 AT E519755T1
Authority
AT
Austria
Prior art keywords
modulators
vitamin
receptor
secosteroidal
zxb
Prior art date
Application number
AT05854993T
Other languages
English (en)
Inventor
Quanrong Shen
Alan Warsawsky
Ying Yee
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE519755T1 publication Critical patent/ATE519755T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05854993T 2004-12-21 2005-12-19 Modulatoren des vitamin-d-rezeptors ATE519755T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63802904P 2004-12-21 2004-12-21
PCT/US2005/046361 WO2006069154A2 (en) 2004-12-21 2005-12-19 Vitamin d receptor modulators

Publications (1)

Publication Number Publication Date
ATE519755T1 true ATE519755T1 (de) 2011-08-15

Family

ID=36602286

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05854993T ATE519755T1 (de) 2004-12-21 2005-12-19 Modulatoren des vitamin-d-rezeptors

Country Status (11)

Country Link
US (1) US7659296B2 (de)
EP (1) EP1836177B1 (de)
JP (1) JP2008524260A (de)
KR (1) KR100931777B1 (de)
AT (1) ATE519755T1 (de)
BR (1) BRPI0519152A2 (de)
CA (1) CA2589667A1 (de)
ES (1) ES2369510T3 (de)
IL (1) IL183779A0 (de)
MX (1) MX2007007225A (de)
WO (1) WO2006069154A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1511740T3 (da) 2002-05-29 2009-08-24 Lilly Co Eli Vitamin-D-receptor-modulatorer af phenyl-thiophen-typen
ES2319984T3 (es) 2002-11-22 2009-05-18 Eli Lilly And Company Moduladores del receptor de vitamina d.
WO2005051898A2 (en) 2003-11-20 2005-06-09 Eli Lilly And Company Vitamin d receptor modulators
CA2544501A1 (en) 2003-11-20 2005-06-09 Eli Lilly And Company Vitamin d receptor modulators
WO2005051938A1 (en) 2003-11-20 2005-06-09 Eli Lilly And Company Vitamin d receptor modulators
JP4717006B2 (ja) 2003-11-20 2011-07-06 イーライ リリー アンド カンパニー ビタミンｄ受容体モジュレータ
BRPI0519494A2 (pt) 2004-12-21 2009-02-03 Lilly Co Eli composto, derivado de prà-droga do composto, derivado de sal do composto, formulaÇço,e, uso de um composto

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1511740T3 (da) 2002-05-29 2009-08-24 Lilly Co Eli Vitamin-D-receptor-modulatorer af phenyl-thiophen-typen
ES2319984T3 (es) 2002-11-22 2009-05-18 Eli Lilly And Company Moduladores del receptor de vitamina d.
WO2004063348A2 (en) 2003-01-10 2004-07-29 Eli Lilly And Company Vesicant treatment with phenyl-thiophene type vitamin d receptor modulators
EP1587906A2 (de) 2003-01-10 2005-10-26 Eli Lilly And Company Vesikansbehandlung mit vitamin-d-rezeptormodulatoren des phenyl-phenyl-typs
WO2005051898A2 (en) 2003-11-20 2005-06-09 Eli Lilly And Company Vitamin d receptor modulators
CA2546729A1 (en) 2003-11-20 2005-06-09 Eli Lilly And Company Phenyl-furan compounds as vitamin d receptor modulators
CA2544501A1 (en) 2003-11-20 2005-06-09 Eli Lilly And Company Vitamin d receptor modulators
WO2005051938A1 (en) * 2003-11-20 2005-06-09 Eli Lilly And Company Vitamin d receptor modulators
JP4717006B2 (ja) 2003-11-20 2011-07-06 イーライ リリー アンド カンパニー ビタミンｄ受容体モジュレータ
BRPI0519494A2 (pt) 2004-12-21 2009-02-03 Lilly Co Eli composto, derivado de prà-droga do composto, derivado de sal do composto, formulaÇço,e, uso de um composto

Also Published As

Publication number Publication date
MX2007007225A (es) 2007-08-21
KR20070086470A (ko) 2007-08-27
ES2369510T3 (es) 2011-12-01
JP2008524260A (ja) 2008-07-10
EP1836177A2 (de) 2007-09-26
BRPI0519152A2 (pt) 2008-12-30
CA2589667A1 (en) 2006-06-29
KR100931777B1 (ko) 2009-12-14
WO2006069154A3 (en) 2006-12-21
US7659296B2 (en) 2010-02-09
US20080119407A1 (en) 2008-05-22
WO2006069154A2 (en) 2006-06-29
EP1836177B1 (de) 2011-08-10
IL183779A0 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
SE0301010D0 (sv) Novel compounds
SE0301009D0 (sv) Novel compounds
ATE433447T1 (de) Pyrimiidinverbindungen
TW200612892A (en) Novel compounds
EA200900048A1 (ru) Новые карбонилированные (аза)циклогексаны в качестве лигандов d3 рецептора дофамина
SE0303180D0 (sv) Novel compounds
SE0302232D0 (sv) Novel Compounds
MX2009005462A (es) Analogos de 7,8-saturados-4,5-epoxi-morfinano.
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
WO2003086306A3 (en) 5ht2c receptor modulators
EA201001682A1 (ru) Производные фенил- и бензодиоксинилзамещенных индазолов
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
LT2006017A (en) 2-(quinoxalin-5-ylsulfonylamino)-benzamide compounds as cck2 modulators
MX2009005461A (es) N-oxidos de analogos de 4,5-epoxi-morfinano.
TW200833670A (en) Novel compounds 569
TW200612936A (en) Indole derivatives
SE0401762D0 (sv) Novel compounds
MX2009003981A (es) Agentes moduladores del receptor de calcio.
IL183779A0 (en) Vitamin d receptor modulators
TW200738659A (en) Novel compounds
IL183655A0 (en) Vitamin d receptor modulators
WO2007130823A3 (en) Polycyclic heterocyclic compounds and their use as modulators of the metabotropic glutamate 5 receptor
BRPI0506477A (pt) compostos farmaceuticamente úteis e inovadores
SE0300091D0 (sv) Novel compounds
DK1730147T3 (da) Substituerede 1,4,8-triazaspiro[4.5]decan-2-on-forbindelser til behandling af fedme

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties